Mecasermin is recombinant human IGF-1; it is the only treatment for severe primary IGF-1 deficiency (growth hormone insensitivity), approved in the United States in 2005 and in Europe in 2007.
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'IGF-1 (Mecasermin / recombinant human IGF-1)' with aliases rhIGF-1, Mecasermin, Increlex, Somatomedin C, IGF-I · 2026-09-27 12:04 · somebody
kind set kind set to peptide: palette r2 · 2026-09-27 12:04 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 12:04 · somebody
fact added summary: Mecasermin is recombinant human IGF-1; it is the only treatment for severe primary IGF-1 deficiency (growth hormone inse · 2026-09-27 12:04 · somebody
fact added summary: In a phase 1 study in 12 girls with MECP2 mutations (9 with Rett syndrome), mecasermin reached the cerebrospinal fluid w · 2026-09-27 12:04 · somebody
citation added pmid 19707272 cited as established: Mecasermin for severe primary IGF-1 deficiency: regulatory approval and long-term use · 2026-09-27 12:04 · somebody
citation added pmid 24623853 cited as emerging: Mecasermin safety and preliminary efficacy in Rett syndrome (phase 1) · 2026-09-27 12:04 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.